Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

The U.S. Food and Drug Administration announced today that it has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin.

25 Mar 2013

Alarming report on persistent side effects of antidepressant drugs published online

An alarming report from patient online websites on persistent side effects of antidepressant drugs has been published in one of the last issue of Psychotherapy and Psychosomatics by investigators from the University of Bologna and North America.

21 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

Dotarem gets FDA approval for use in patients undergoing CNS MRI

The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging of the brain, spine and associated tissues of patients ages 2 years and older.

21 Mar 2013

Antagonist drug Emend halts brain tumor growth

New research from the University of Adelaide has shown for the first time that the growth of brain tumors can be halted by a drug currently being used to help patients recover from the side effects of chemotherapy.

20 Mar 2013

Multidrug-resistant tuberculosis (MDR-TB) patients and Médecins Sans Frontières medical staff call for urgent action

If measures to tackle multidrug-resistant tuberculosis (MDR-TB) are not significantly stepped up, including addressing barriers that prevent both research into better drug combinations and treatment scale up, MDR-TB rates will continue to increase worldwide and a historic opportunity to improve abysmal cure rates will have been squandered, medical humanitarian organisation Médecins Sans Frontières warned today.

20 Mar 2013

ProtiDiet High Protein Chocolate Dream Bars may contain Salmonella, warns FDA

Pro-Amino International Inc. is recalling protein bars which may contain Salmonella. The product is the ProtiDiet High Protein Chocolate Dream Bar, sold in 210 gram (7.4 oz.) packages, 7 bars per package, bearing UPC 6 21498 42238 1, lot code CR 18 13B, and Best Before date of 2015-08.

19 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

Studies show local chemotherapy more effective in reducing tumor growth than regular chemotherapy

Reducing the growth of a tumor by localized delivery of cancer medication can be achieved by using a combination of ultrasound, temperature-sensitive nanoparticles and MRI.

14 Mar 2013

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Pharmaceutical scientists at the University of Sunderland have been awarded £125,000 by the Cystinosis Foundation (CF) UK to fund the next stage of their research into a rare genetic disease.

7 Mar 2013

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags.

6 Mar 2013

FDA accepts AMAG’s Feraheme sNDA for review

AMAG Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012.

6 Mar 2013

Phase III success with extended-release carbidopa–levodopa formulation

An extended-release formulation of carbidopa–levodopa reduces the amount of off-time in patients with Parkinson’s disease, show results from a phase III randomized trial.

5 Mar 2013

Cognitive behavioral therapy brings relief to people with diabetic neuropathies, researchers find

Researchers at Boston University School of Medicine and VA Boston Healthcare System have found that cognitive behavioral therapy can help relieve pain for people with painful diabetic neuropathies.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAA), while fire ant allergy sufferers know allergy shots can save their life, more than 60 percent do not adhere to treatment guidelines.

4 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013

AHRF to present free symposium on dizziness and balance disorders

The American Hearing Research Foundation will present a free, day-long educational symposium on dizziness and balance disorders on Saturday, April 6 at the Hilton Suites Chicago/Oakbrook in Oakbrook, Illinois.

27 Feb 2013

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

Nausea News and Research

Further Reading

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

Alarming report on persistent side effects of antidepressant drugs published online

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Dotarem gets FDA approval for use in patients undergoing CNS MRI

Antagonist drug Emend halts brain tumor growth

Multidrug-resistant tuberculosis (MDR-TB) patients and Médecins Sans Frontières medical staff call for urgent action

ProtiDiet High Protein Chocolate Dream Bars may contain Salmonella, warns FDA

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

Studies show local chemotherapy more effective in reducing tumor growth than regular chemotherapy

University of Sunderland pharmaceutical scientists receive CFUK grant for research into cystinosis

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

FDA accepts AMAG’s Feraheme sNDA for review

Phase III success with extended-release carbidopa–levodopa formulation

Cognitive behavioral therapy brings relief to people with diabetic neuropathies, researchers find

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

AHRF to present free symposium on dizziness and balance disorders

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News